Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor

General Pharmacology

Volumn 31, Issue 1, 1998, Pages 93-99

  Kinugawa, Toru ^a   Ogino, Kazuhide ^a   Kato, Masahiko ^a   Furuse, Yoshiyuki ^a   Shimoyama, Masaki ^a   Mori, Masatake ^a   Endo, Akihiro ^a   Kato, Tatsuo ^a   Omodani, Hiroki ^a   Osaki, Shuichi ^a   Miyakoda, Hiroyuki ^a   Hisatome, Ichiro ^a   Shigemasa, Chiaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

ACE inhibitor; Cardiopulmonary exercise test; Congestive heart failure; Neurohumoral factor; Spironolactone

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; LOOP DIURETIC AGENT; NEUROHORMONE; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; EXERCISE; FEMALE; HEART FAILURE; HEART RATE; HUMAN; MALE; NATRIURESIS; NORADRENALIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; OXYGEN CONSUMPTION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIURETICS; ECHOCARDIOGRAPHY; ELECTROLYTES; EXERCISE TEST; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NEUROSECRETORY SYSTEMS; PULMONARY VENTILATION; SPIRONOLACTONE;

EID: 0032125642     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(97)00396-0     Document Type: Article

References (47)

1. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342, 821-828.
2. Barr C.S., Lang C.C., Hanson J., Arnott M., Kennedy N., Struthers A.D. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. 76:1995;1259-1265.
3. Bayliss J., Norell M., Anson R.C., Sutton G., Wilson P.P. Untreated heart failure. clinical and neuroendocrine effects of introducing diuretics Br. Heart J. 57:1987;17-22.
4. Beaver W.L., Wasserman K., Whipp B.J. A new method for detecting the anaerobic threshold by gas exchange. J. Appl. Physiol. 60:1986;2020-2027.
5. Borghi C., Boschi S., Ambrosioni E., Melandri G., Branzi A., Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J. Clin. Pharmac. 33:1993;40-45.
6. Captopril-Digoxin Multicenter Research Group Comparative effects of therapy with captopril and digoxin in patients with mild-to-moderate heart failure. JAMA. 259:1988;539-544.
7. Captopril Multicenter Research Group A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J. Am. Coll. Cardiol. 2:1983;755-763.
8. Cheitlin M.D., Byrd R., Benowitz N., Liu E., Modin G. Amiloride improves hemodynamics in patients with chronic congestive heart failure treated with chronic digoxin and diuretics. Cardiovasc. Drug Ther. 5:1991;719-726.
9. Cohn N.J., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., Simon A.B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N. Engl. J. Med. 311:1984;819-823.
10. CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus) N. Engl. J. Med. 316:1987;1429-1435.
11. Dahlstrom U., Karlsson E. Captoril and spironolactone therapy in patients with refractory congestive heart failure. Curr. Ther. Res. 51:1992;235-248.
12. Dzau V.J. Vascular renin angiotensin pathways. a new therapeutic target J. Cardiovasc. Pharmac. 10(Suppl. 7):1992;S13-S26.
13. Francis G.S., Benedict C., Johnstone D.E., Kirlin P.C., Nicklas J., Liang C., Kubo S.H., Rudin-Toresky E., Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. a substudy of the studies of left ventricular dysfunction (Solvd) Circulation. 82:1990;1724-1729.
14. Haerer W., Bauer U., Sultan N., Cernoch K., Mouselimis N., Fehske K.J., Hetzel M., Stauch M., Hombach V. Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure. a placebo-controlled trial Cardiovasc. Drugs Ther. 4:1990;515-522.
15. ® ANP. human atrial natriuretic peptide IRMA kit Kiso to Rinsyo. 25:1991;455-462.
16. Henry R. J. (1968) Clinical Chemistry: Principles and Techniques. pp. 655-656. Harper & Row, New York.
17. Hensen J., Abraham W.T., Durr J.A., Schrier R.W. Aldosterone in congestive heart failure. analysis of determinants and role in sodium retention Am. J. Nephrol. 11:1991;441-446.
18. Hirsch A. T., Dzau V. J. and Creager M.A. (1987) Baroreceptor function in congestive heart failure: effect on neurohumoral activation and regional vascular resistance. Circulation 75(Suppl. IV), IV-36-IV-48.
19. Husain A. The chymase-angiotensin system in humans. J. Hypertens. 11:1993;1155-1159.
20. Ikram H., Webster M.W.I., Nicholls M.G., Lewis G.R.J., Richards A.M., Crozier I.G. Combined spironolactone and converting enzyme inhibitor therapy for refractory heart failure. Aust. N. Z. J. Med. 16:1986;61-63.
21. Kinugawa T., Ogino K., Kitamura H., Miyakoda H., Saitoh M., Hasegawa J., Kotake H., Mashiba H. Response of sympathetic nervous system activity to exercise in patients with congestive heart failure. Eur. J. Clin. Invest. 21:1991;542-547.
22. Kinugawa T., Ogino K., Kitamura H., Saitoh M., Omodani H., Osaki S., Hisatome I., Miyakoda H. Catecholamines, renin-angiotensin-aldosterone system, and atrial natriuretic peptide at rest and during submaximal exercise in patients with congestive heart failure. Am. J. Med. Sci. 312:1996;110-117.
23. Kirlin P.C., Grekin R., Das S., Ballor E., Johnson T., Pitt B. Neurohumoral activation during exercise in congestive heart failure. Am. J. Med. 81:1986;623-629.
24. Morimoto T., Aoyama M., Gotoh E., Shionoiri H. A method of radioimmunoassay of plasma angio-tensin II using florisil. Folia Endocrinol. Jpn. 59:1983;215-229.
25. Nishikimi T., Kohno M., Matsuura T., Akioka K., Teragaki M., Yasuda M., Oku H., Takeuchi K., Takeda T. Effect of exercise on circulating atrial natriuretic polypeptide in valvular heart disease. Am. J. Cardiol. 58:1986;1119-1120.
26. 125I] PRA Kit. Horumon to Rinsyou. 28:1980;63-69.
27. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation. 77:1988;721-730.
28. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor. implications for therapy Cardiovasc. Drugs Ther. 9:1995;145-149.
29. Pouleur H., Konstam M. A., Benedict C. R., Donckier J., Galanti L., Melin J., Kinan D., Ahn S. and Rousseau M. F. (1993) Progression of LV dysfunction during enalapril therapy: relationship with neurohormonal reactivation. Circulation. 88, i-293.
30. RALES Investigators Effectiveness of spironolactone added to an angiotension-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol. 78:1996;902-907.
31. Rousseau M.F., Konstam M.A., Benedict C.R., Donckier J., Galanti L., Melin J., Kinan D., Ahn S., Ketesleger J.M., Pouleur H. Progression of LV dysfunction secondary to coronary artery disease. sustained neurohormonal activation and effects of ibopamine therapy during long term therapy with ACE inhibitor Am. J. Cardiol. 73:1994;488-493.
32. Shionoiri H., Minamizawa K., Sugimoto K., Abe Y., Suzuki T., Ito S., Morishita R., Higaki J., Ogiwara T. Fundamental and clinical studies on SPAC-S Aldosterone RIA Kit. Igaku to Yakugaku. 21:1989;293-302.
33. SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325:1991;293-302.
34. Staessen J., Lijnen P., Fagard R., Verscheren L.J., Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J. Endocrinol. 91:1981;457-465.
35. Stampfer M., Epstein S.E., Beiser G.D., Braunwald E. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function. Circulation. 37:1968;900-911.
36. Struthers A.D. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J. Cardiac Failure. 2:1996;47-54.
37. Sue D.Y., Wasserman K., Morrica R.B., Casburi R. Measurement of anaerobic threshold by V-slope method in patients with chronic obstructive lung disease and normal subjects. Chest. 94:1988;931-938.
38. Sullivan M.J., Green H.J., Cobb F.R. Altered skeletal muscle metabolic response to exercise in patients with heart failure. Circulation. 84:1991;1597-1607.
39. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L., for The CONSENSUS Trial Study Group Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 82:1990;1730-1736.
40. Teichholz L.E., Kreulen T., Herman M.V., Gorlin R. Problems in echocardiographic volume determinations. echocardiographic-angiographic correlations in the presence or absence of asynergy Am. J. Cardiol. 37:1976;7-11.
41. Textor S.C., Bravo E.L., Fouad F.M., Tarazi R.C. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am. J. Med. 73:1982;719-725.
42. van den Meiracker A.H., Man in't Veld A.J., Vaneck H.J.R. Partial escape of ACE inhibition during prolonged ACE inhibitor treatment. does it exist and does it affect the antihypertensive response? Hypertension. 10:1992;803-812.
43. van Vilet A., Donker A.J.M., Nauta J.J.P., Verheugt F.W.A. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am. J. Cardiol. 71:1993;21A-28A.
44. Wasserman K. The anaerobic threshold measurement to evaluate exercise performance. Am. Rev. Respir. Dis. 129(Suppl.):1984;S35-S40.
45. Wasserman K., Whipp B.J. Exercise physiology in health and disease. Am. Rev. Respir. Dis. 112:1975;219-249.
46. Willson J.R., Martin J.L., Schwartz D., Ferraro N. Exercise intolerance in patients with chronic heart failure. role of impaired nutritive flow to skeletal muscle Circulation. 69:1984;1079-1087.
47. Yoshimura M., Komori T., Nakanishi T., Takahashi H. Estimation of sulphoconjugated catecholamine concentrations in plasma by high-performance liquid chromatography. Ann. Clin. Biochem. 30:1993;135-141.